Malignancy-associated dermatomyositis: Retrospective caseecontrol study from a single tertiary care center
To the Editor: Diagnosis of dermatomyositis often prompts malignancy screening. However, evidencebased malignancy screening guidelines are lacking. Two meta-analyses have investigated which malignancies occur with greater incidence in this population. 1, 2 One analysis highlights the need for more data from Western populations, especially the United States. 2 Hence, we characterized a malignancy-associated dermatomyositis cohort from a US tertiary care center.
An institutional review boardeapproved search of Cleveland Clinic's medical records led to the identification of malignancy-associated dermatomyositis patients. Inclusion required meeting Bohan and Peter dermatomyositis criteria. 3 Amyopathic dermatomyositis patients met Sontheimer criteria. 4 We compared this cohort with age-matched and sex-matched control dermatomyositis patients without malignancy and with $5 years follow-up from diagnosis.
We focused analyses on 50 patients (33 women, 17 men) with #3 years between dermatomyositis and malignancy diagnoses (Fig 1) . Average age at malignancy diagnosis was 58.5 years (median 6 standard deviation, 61.5 6 12.8 years), 58.3 years for classic dermatomyositis patients, and 50.1 years for amyopathic dermatomyositis patients. Malignancy distribution of the 50 patients were as follows: 9 lung, 7 colon, 6 breast, 5 hematologic, 4 oropharyngeal, 4 ovarian, 4 renal, 3 thyroid, 2 esophageal, 2 prostate, 1 thymic, 1 melanoma, 1 gastric, and 1 testicular. The most common malignancies were in accordance with meta-analyses results.
1,2 Thus, the risk-benefit ratio of dermatomyositis malignancy screening seems most favorable when focused on malignancies occurring with increased incidence in this population.
Of patients who developed malignancy after the dermatomyositis diagnosis (DM-MAL), 57.1% (16/ 28) had malignancy diagnosed #12 months and 75% (21/28) #2 years after the dermatomyositis diagnosis. This data suggest screening is most beneficial when aimed at malignancies occurring with increased incidence in dermatomyositis patients. In patients with symptoms suggesting a malignancy, diagnostic tests aimed these symptoms seem more appropriate than general screening.
Limiting screening to patients with clinical features commonly associated with malignancy-associated dermatomyositis might be useful to avoid over-testing. Features associated with malignancy-associated dermatomyositis in previous studies include age [52 years, skin necrosis, TIF1 autoantibodies, and dysphagia. 5 Alternatively, interstitial lung disease (ILD) and Raynaud phenomenon have been found to protect against malignancy. 5 In our cohort, dysphagia was significantly associated with underlying malignancy (2.92x higher in malignancy-associated dermatomyositis, P ¼ .012) ( Table I) . As expected, dysphagia was significantly associated with underlying malignancy (P ¼ .015) in classic dermatomyositis patients (22/43 [51.2%] malignancy-associated dermatomyositis vs 11/43 [25.6%] controls) but not in amyopathic dermatomyositis patients, who lacked evidence of esophageal myositis. Although dysphagia was found to suggest underlying malignancy in other studies, to our knowledge none of these studies were case-controlled. Our data suggests dysphagia might be an independent risk factor for underlying malignancy in classic dermatomyositis patients.
ILD was diagnosed in 4 classic dermatomyositis patients (1 lung, 2 renal, 1 colon carcinomas), potentially refuting the protective nature of ILD. The percentage of our cohort with ILD (8.0%) is lower than expected in dermatomyositis patients without malignancy, though, and our relatively small cohort precludes any definitive statement. However, a meta-analysis found several studies failed to show with confidence that ILD was protective for underlying malignancy. 5 Taken together, this data underscores the importance of reporting more cohorts, as features suggestive of and protective of malignancy in specific cohorts might not be generalizable.
Of note, 2 of the 5 patients with malignancyassociated dermatomyositis who were tested were positive for TIF1 antibodies; in comparison 1 of 4 patients were positive in the dermatomyositis control group. In our cohort, the most common test used to demonstrate malignancy is computed tomography scanning. Patients with malignancy were more likely to die before study cessation (P # .001).
The goals of screening are to decrease morbidity and mortality in malignancy-associated dermatomyositis patients, while minimizing harms and costs. Our data suggest malignancy screening is most beneficial in dermatomyositis patients [50 years old with dysphagia (in the setting of classic dermatomyositis) when performed #12 months after diagnosis and when tests are aimed at detecting malignancies known to occur with increased incidence in dermatomyositis patients. Future research on malignancy-associated dermatomyositis is warranted. Interstitial lung disease 1 (5) 3 (11) 4 (8) 10 (20) Values are n (%) unless indicated otherwise. Forty-three patients had classic DM, and 7 had amyopathic DM. The 50 malignancy-associated DM patients self-identified as white (n ¼ 22), black (n ¼ 5), Asian (n ¼ 3), Hispanic (n ¼ 1), or did not specify (n ¼ 19). Data represents number of patients with the DM feature noted at any time during course of DM disease. DM, Dermatomyositis; DM-MAL, malignancy developing after dermatomyositis diagnosis; DM-no MAL, malignancy not developing after dermatomyositis diagnosis; MAL-DM, dermatomyositis developing after diagnosis of malignancy. *DM-no MAL represents a cohort of age-matched and sex-matched control patients with confirmed DM but without malignancy and $5 years data from DM diagnosis seen at our institution. y Statistically significant differences (P \ .05) between the 50 malignancy-associated DM patients and the 50 DM-no MAL patients. Statistical tests were performed by using SPSS 24.0 software (IBM, Armonk, NY). Descriptive statistics included mean, standard deviation, median, and range. Nominal variables were assessed using chi-squared analyses (or Fisher's exact if assumptions violated) and odds ratios. For numerical variables, independent samples t tests were used if assumption of equal variances was satisfied by using Levene test. If equal variances could not be assumed, Mann-Whitney U tests were used.
Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies
To the Editor: Biologic switching has become a common practice in dermatology clinics. Although outcomes of switching between older generation biologics have been extensively studied, the effectiveness and safety of switching patients between interleukin (IL) 17A antagonists is unknown. As such, dermatologists might be hesitant to attempt therapy with a second IL-17A antagonist, electing instead to try an alternative biologic. Therefore, we aimed to investigate the likelihood that secukinumab nonresponders will respond to ixekizumab. Furthermore, we assessed whether or not individuals who experienced an adverse event (AE) to secukinumab experienced the same fate with ixekizumab. We conducted a Canadian multicenter retrospective study of patients $18 years of age with moderate-to-severe plaque psoriasis (Psoriasis Area and Severity Index [PASI] $10 at baseline) and treated with ixekizumab 80-mg therapy after discontinuation of secukinumab 300 mg. Responders were patients who achieved a 75% reduction in PASI (PASI 75) or physician global assessment (PGA) of 0 (clear) or 1 (almost clear) when PASI was not documented.
Patient demographics and clinical outcomes of the 17 patients who met inclusion criteria are summarized in Table I . Of the 17 patients who were secukinumab nonresponders, 15 (88.2%) responded to ixekizumab following 12 weeks of treatment. This was similar to the IL-17Aenaive patients treated with ixekizumab in randomized controlled trials (UNCOVER-1, 89.1; UNCOVER-2, 89.7; UNCOVER-3, 87.3%).
1,2
In subset analysis, all primary nonresponders to secukinumab (n ¼ 4) achieved PASI 75 or PGA 0/1 after 12 weeks of ixekizumab treatment compared with 8 of 9 (88.9%) secondary nonresponders and 3 of 4 (75%) patients who stopped secukinumab because of intolerance or a nondrug-related reason (Fig 1) . Of note, PASI 75 response was shown to be strongly associated with the reason for switching for individuals who switched between tumor necrosis factor (TNF) inhibitors. [3] [4] [5] Piaserico et al suggested individuals who experienced secondary loss of efficacy to one TNF-inhibitor or stopped treatment due to an AE were more likely to achieve PASI 75 at week 12 than those who were primary nonresponders. Our findings suggest the same might not be true for IL-17A antagonists, where efficacy outcomes did not correlate with reason for secukinumab discontinuation. Similarly, duration of secukinumab therapy had no affect on efficacy outcomes, with 75.0% (3/4), 90.0% (9/10), and 100% (3/3) of patients responding to ixekizumab after 
